EXPLORING IMMUNE-RELATED HUB GENES IN PARKINSON’S DISEASE USING INTEGRATIVE BIOINFORMATICS APPROACH

Main Article Content

Muhammad Abbas
Hafeez Ullah
Zarrien Fatima
Rana Adnan Ali
Iffat Amin
Muhammad Aneeque Ijaz
Aqeela Iqbal
Muhammad Qasim Hasan
Muhammad Hassan
Sanwal Mehmood

Keywords

PD, GSE20141, DEGs, Hub genes

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction and the loss of dopaminergic neurons. Emerging evidence suggests that immune system dysregulation and neuroinflammation play key roles in PD pathogenesis. In this study, we aimed to explore immune-related hub genes and associated signaling pathways using bioinformatics analysis of the GSE20141 dataset. We identified 250 differentially expressed genes (DEGs) and constructed a protein-protein interaction (PPI) network to pinpoint key hub genes. Four hub genes, FGF17, MED26, LCK, and RPS12, were identified as central players in the network, and functional enrichment analysis revealed significant involvement of several immune-related pathways.Key pathways enriched in our analysis included the JAK-STAT signaling pathway, NF-kappa B signaling pathway, and T cell receptor signaling pathway, all of which are known to regulate immune responses and inflammation in neurodegenerative diseases. Interestingly, our study also identified pathways less commonly associated with PD, such as the adipocytokine signaling pathway and osteoclast differentiation, suggesting a potential link between metabolic dysregulation and neuroinflammation. Our findings highlight both established and novel immune mechanisms in PD, suggesting potential therapeutic targets aimed at modulating immune responses. This study provides valuable insights into the complex immune landscape of PD and emphasizes the importance of immune modulation in understanding and treating this debilitating disease. Further research is needed to validate the role of the identified hub genes and pathways and to explore their potential as targets for PD therapy.

Abstract 92 | pdf Downloads 16

References

1. Khan AU, Akram M, Daniyal M, Zainab R. Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder. International Journal of Neuroscience. 2019; 129: 55-93.
2. Kalia LV, Lang AE. Parkinson's disease. The Lancet. 2015; 386: 896-912.
3. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. Journal of neural transmission. 2015; 122: 1429-40.
4. Rana AQ, Ahmed US, Chaudry ZM, Vasan S. Parkinson’s disease: a review of non-motor symptoms. Expert review of neurotherapeutics. 2015; 15: 549-62.
5. Cherian A, Divya K. Genetics of Parkinson's disease. Acta Neurologica Belgica. 2020: 1-9.
6. Lill CM. Genetics of Parkinson's disease. Molecular and cellular probes. 2016; 30: 386-96.
7. Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram A, Karunakaran R, et al. Alpha-synuclein aggregation in Parkinson's disease. Frontiers in medicine. 2021; 8: 736978.
8. Bhatia V, Sharma S. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer's disease. Journal of the neurological sciences. 2021; 421: 117253.
9. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, et al. Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease. Clinical neuroscience research. 2006; 6: 261-81.
10. Ferrari CC, Tarelli R. Parkinson′ s disease and systemic inflammation. Parkinson’s disease. 2011; 2011: 436813.
11. Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Molecular neurodegeneration. 2018; 13: 51.
12. Wallings RL, Herrick MK, Tansey MG. LRRK2 at the interface between peripheral and central immune function in Parkinson’s. Frontiers in Neuroscience. 2020; 14: 443.
13. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau W-C, Ledoux P, et al. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic acids research. 2005; 33: D562-D6.
14. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006; 6: 772-83.
15. Maner BS, Dupuis L, Su A, Jueng JJ, Harding TP, Meisenheimer J, et al. Overview of genetic signaling pathway interactions within cutaneous malignancies. Journal of Cancer Metastasis and Treatment. 2020; 6: N/A-N/A.
16. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. Journal of cell science. 2004; 117: 1281-3.
17. Zhang Y, Zhang Y, Gu W, Sun B. TH1/TH2 cell differentiation and molecular signals. T helper cell differentiation and their function. 2014: 15-44.
18. Joshi T, Singh AK, Haratipour P, Sah AN, Pandey AK, Naseri R, et al. Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. Journal of Cellular Physiology. 2019; 234: 17212-31.
19. Pal R, Tiwari PC, Nath R, Pant KK. Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease. Neurological research. 2016; 38: 1111-22.
20. Singh SS, Rai SN, Birla H, Zahra W, Rathore AS, Singh SP. NF-κB-mediated neuroinflammation in Parkinson’s disease and potential therapeutic effect of polyphenols. Neurotoxicity Research. 2020; 37: 491-507.
21. Candelise N, Scaricamazza S, Salvatori I, Ferri A, Valle C, Manganelli V, et al. Protein aggregation landscape in neurodegenerative diseases: Clinical relevance and future applications. International journal of molecular sciences. 2021; 22: 6016.
22. Earls RH, Lee J-K. The role of natural killer cells in Parkinson’s disease. Experimental & molecular medicine. 2020; 52: 1517-25.